非小细胞肺癌组织PD-L1的表达及其与临床因素的关系

发布时间：2018-11-15 09:45

【摘要】：目的:探索程序性死亡配体1(programmed death-ligand 1,PD-L1)在中国非小细胞肺癌(non-small cell lung carcinoma,NSCLC)患者肿瘤组织中的表达水平及影响因素。方法:免疫组织化学法检测2008年4月至2014年8月天津医科大学肿瘤医院122例NSCLC初治患者肿瘤组织中PD-L1、PD-1和CD3~+T细胞表达情况,采用χ~2和kruskal-wallis检验分析PDL1表达在临床因素中分布差异性,用Person检验和Spearman检验分析PD-L1表达与EGFR基因型、CD3~+T细胞数量及淋巴细胞PD-1表达的相关性,以及原发灶与淋巴结PD-L1表达相关性。结果:所有患者原发灶肿瘤细胞PD-L1表达百分比中位值1.5%(0~93.2%),PD-L1表达在TNM分期分布上有统计学差异(P=0.003),与TNM分期呈显著正相关(r=0.273,P=0.002),与性别、年龄、有无吸烟史、肿瘤最大径、病理类型、CEA水平分布无显著相关(P0.05);PD-L1表达水平与CD3~+T细胞数量、淋巴细胞PD-1表达水平无相关性,PD-L1表达阴性、低表达和高表达与表皮生长因子受体(epidermal growth factor receptor,EGFR)基因突变亦无显著相关(P0.05);48例有淋巴结转移的NSCLC患者原发灶与相应转移淋巴结肿瘤细胞PDL1表达水平无统计学相关性(P0.05)。结论:NSCLC患者原发灶肿瘤细胞PD-L1表达在TNM分期分布上有差异,与CD3~+T细胞数量、淋巴细胞PD-1表达水平、EGFR基因突变情况无相关性;原发灶与相应转移淋巴结之间肿瘤细胞PD-L1的表达亦没有相关性。
[Abstract]:Objective: to investigate the expression of programmed death ligand 1 (programmed death-ligand 1) PD-L1 in Chinese non-small cell lung cancer (non-small cell lung carcinoma,NSCLC) and its influencing factors. Methods: from April 2008 to August 2014, the expression of PD-L1,PD-1 and CD3~ T cells in the tumor tissues of 122 patients with NSCLC in Tianjin Medical University Oncology Hospital were detected by immunohistochemical method. 蠂 ~ 2 and kruskal-wallis tests were used to analyze the difference of PDL1 expression in clinical factors. Person test and Spearman test were used to analyze the correlation between PD-L1 expression and EGFR genotype, CD3~ T cell number and PD-1 expression in lymphocytes. And the expression of PD-L1 in lymph nodes was correlated with the primary lesions. Results: the median value of PD-L1 expression in primary tumor cells was 1.5% (0 93.2%), and the expression of PD-L1 was significantly different in TNM staging (P0. 003). There was a significant positive correlation between the expression of PD-L1 and TNM stage (r = 0. 273, P < 0. 003). P0. 002), there was no significant correlation between sex, age, smoking history, tumor maximum diameter, pathological type and CEA level distribution (P0.05). There was no correlation between the expression of PD-L1 and the number of CD3~ T cells and the expression of PD-1 in lymphocytes. The expression of PD-L1 was negative, while the low and high expression of PD-L1 was associated with the expression of EGF receptor (epidermal growth factor receptor,. There was no significant correlation between EGFR gene mutation and EGFR gene mutation (P0.05). There was no statistical correlation between the expression of PDL1 in 48 NSCLC patients with lymph node metastasis and the corresponding metastatic lymph node tumor cells (P0.05). Conclusion: the expression of PD-L1 in primary tumor cells of NSCLC patients is different in TNM stages, but not correlated with the number of CD3~ T cells, the level of PD-1 expression in lymphocytes and the mutation of EGFR gene. There was no correlation between the expression of PD-L1 in tumor cells and the corresponding metastatic lymph nodes.
【作者单位】：天津医科大学肿瘤医院免疫室国家肿瘤临床医学研究中心天津市"肿瘤防治"重点实验室天津市恶性肿瘤临床医学研究中心天津市肿瘤免疫与生物治疗重点实验室天津医科大学肿瘤医院生物治疗科
【基金】：国家科技支撑计划资助项目(No.2015BA112B12) 国家自然科学基金项目(No.81272221,No.81401887)~~
【分类号】：R734.2

【相似文献】